ABVC BioPharma, Inc.
ABVC
$1.23
-$0.08-6.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -796.00K | 796.00K | -- | -- | 2.00K |
| Total Other Revenue | -- | -- | -- | -- | -11.60K |
| Total Revenue | -796.00K | 796.00K | -- | -- | 2.00K |
| Cost of Revenue | -- | -- | -- | -- | 0.00 |
| Gross Profit | -796.00K | 796.00K | -- | -- | 2.00K |
| SG&A Expenses | 2.17M | 1.93M | 2.26M | 664.10K | 674.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.50K | -2.20K | -- | -- | 45.50K |
| Total Operating Expenses | 2.20M | 1.96M | 2.30M | 693.00K | 752.10K |
| Operating Income | -2.99M | -1.17M | -2.30M | -693.00K | -750.10K |
| Income Before Tax | -3.81M | -1.29M | -2.31M | -944.20K | -796.50K |
| Income Tax Expenses | 0.00 | 500.00 | 23.60K | -- | 0.00 |
| Earnings from Continuing Operations | -3.81M | -1.29M | -2.33M | -944.20K | -796.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 249.50K | 41.00K | 75.80K | 102.10K | 65.00K |
| Net Income | -3.56M | -1.25M | -2.26M | -842.10K | -731.60K |
| EBIT | -2.99M | -1.17M | -2.30M | -693.00K | -750.10K |
| EBITDA | -2.99M | -1.16M | -2.29M | -686.00K | -739.70K |
| EPS Basic | -0.14 | -0.05 | -0.13 | -0.06 | -0.06 |
| Normalized Basic EPS | -0.06 | -0.03 | -0.08 | -0.03 | -0.04 |
| EPS Diluted | -0.15 | -0.05 | -0.13 | -0.06 | -0.06 |
| Normalized Diluted EPS | -0.06 | -0.03 | -0.08 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 24.73M | 23.26M | 17.39M | 14.97M | 13.20M |
| Average Diluted Shares Outstanding | 24.73M | 23.26M | 17.39M | 14.97M | 13.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |